Skip to main content
Erschienen in: General Thoracic and Cardiovascular Surgery 3/2023

30.09.2022 | Original Article

Lymph node dissections and survival in sublobar resection of non-small cell lung cancer ≤ 20 mm

verfasst von: Shinkichi Takamori, Takefumi Komiya, Mototsugu Shimokawa, Emily Powell

Erschienen in: General Thoracic and Cardiovascular Surgery | Ausgabe 3/2023

Einloggen, um Zugang zu erhalten

Abstract

Background

A randomized trial of lobectomy versus segmentectomy for small-sized (≤ 20 mm) non-small cell lung cancer (NSCLC) showed that patients who had undergone segmentectomy had a significantly longer overall survival (OS) than those who had lobectomy. More attention is needed regarding the required extent of thoracic lymphadenectomy in patients with small-sized NSCLC who undergo sublobar resection.

Methods

The National Cancer Database was queried for patients with clinically node-negative NSCLC ≤ 20 mm who had undergone sublobar resection between 2004 and 2017. OS of NSCLC patients by the number of lymph node dissections (LNDs) was analyzed using log-rank tests and Cox proportional hazards model. The cutoff value of the LNDs was set to 10 according to the Commission on Cancer’s recommendation.

Results

This study included 4379 segmentectomy and 23,138 wedge resection cases. The sequential improvement in the HRs by the number of LNDs was evident, and the HR was the lowest if the number of LNDs exceeded 10. Patients with ≤ 9 LNDs had a significantly shorter OS than those with ≥ 10 LNDs (hazard ratio [HR] 1.50, 95% confidence interval [CI] 1.40–1.61, P < 0.0001). Multivariable analysis revealed that performing ≤ 9 LNDs was an independent factor for predicting OS (HR for death: 1.34, 95% CI 1.24–1.44, P < 0.0001). These results remained significant in subgroup analyses by the type of sublobar resection (segmentectomy, wedge resection).

Conclusions

Performing ≥ 10 LNDs has a prognostic role in patients with small-sized NSCLC even if the resection is sublobar.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49. CrossRefPubMed Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49. CrossRefPubMed
3.
Zurück zum Zitat Saji H, Okada M, Tsuboi M, et al. Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (jcog0802/wjog4607l): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial. Lancet. 2022;399(10335):1607–17. CrossRefPubMed Saji H, Okada M, Tsuboi M, et al. Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (jcog0802/wjog4607l): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial. Lancet. 2022;399(10335):1607–17. CrossRefPubMed
4.
Zurück zum Zitat Darling GE, Allen MS, Decker PA, et al. Randomized trial of mediastinal lymph node sampling versus complete lymphadenectomy during pulmonary resection in the patient with n0 or n1 (less than hilar) non-small cell carcinoma: results of the american college of surgery oncology group z0030 trial. J Thorac Cardiovasc Surg. 2011;141(3):662–70. CrossRefPubMedPubMedCentral Darling GE, Allen MS, Decker PA, et al. Randomized trial of mediastinal lymph node sampling versus complete lymphadenectomy during pulmonary resection in the patient with n0 or n1 (less than hilar) non-small cell carcinoma: results of the american college of surgery oncology group z0030 trial. J Thorac Cardiovasc Surg. 2011;141(3):662–70. CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Lardinois D, Suter H, Hakki H, Rousson V, Betticher D, Ris HB. Morbidity, survival, and site of recurrence after mediastinal lymph-node dissection versus systematic sampling after complete resection for non-small cell lung cancer. Ann Thorac Surg. 2005;80(1):268–74 ( Discussion 74-5). CrossRefPubMed Lardinois D, Suter H, Hakki H, Rousson V, Betticher D, Ris HB. Morbidity, survival, and site of recurrence after mediastinal lymph-node dissection versus systematic sampling after complete resection for non-small cell lung cancer. Ann Thorac Surg. 2005;80(1):268–74 ( Discussion 74-5). CrossRefPubMed
6.
Zurück zum Zitat Wu Y, Huang ZF, Wang SY, Yang XN, Ou W. A randomized trial of systematic nodal dissection in resectable non-small cell lung cancer. Lung Cancer. 2002;36(1):1–6. CrossRefPubMed Wu Y, Huang ZF, Wang SY, Yang XN, Ou W. A randomized trial of systematic nodal dissection in resectable non-small cell lung cancer. Lung Cancer. 2002;36(1):1–6. CrossRefPubMed
7.
Zurück zum Zitat Hishida T, Saji H, Watanabe SI, et al. A randomized phase iii trial of lobe-specific vs. systematic nodal dissection for clinical stage i–ii non-small cell lung cancer (jcog1413). Jpn J Clin Oncol. 2018;48(2):190–4. CrossRefPubMed Hishida T, Saji H, Watanabe SI, et al. A randomized phase iii trial of lobe-specific vs. systematic nodal dissection for clinical stage i–ii non-small cell lung cancer (jcog1413). Jpn J Clin Oncol. 2018;48(2):190–4. CrossRefPubMed
8.
Zurück zum Zitat Wang Y-N, Yao S, Wang C-L, et al. Clinical significance of 4l lymph node dissection in left lung cancer. J Clin Oncol. 2018;36(29):2935–42. CrossRefPubMed Wang Y-N, Yao S, Wang C-L, et al. Clinical significance of 4l lymph node dissection in left lung cancer. J Clin Oncol. 2018;36(29):2935–42. CrossRefPubMed
10.
Zurück zum Zitat Howington JA, Blum MG, Chang AC, Balekian AA, Murthy SC. Treatment of stage i and ii non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American college of chest physicians evidence-based clinical practice guidelines. Chest. 2013;143(5 Suppl):e278S-e313S. CrossRefPubMed Howington JA, Blum MG, Chang AC, Balekian AA, Murthy SC. Treatment of stage i and ii non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American college of chest physicians evidence-based clinical practice guidelines. Chest. 2013;143(5 Suppl):e278S-e313S. CrossRefPubMed
11.
Zurück zum Zitat Okada M, Koike T, Higashiyama M, Yamato Y, Kodama K, Tsubota N. Radical sublobar resection for small-sized non-small cell lung cancer: a multicenter study. J Thorac Cardiovasc Surg. 2006;132(4):769–75. CrossRefPubMed Okada M, Koike T, Higashiyama M, Yamato Y, Kodama K, Tsubota N. Radical sublobar resection for small-sized non-small cell lung cancer: a multicenter study. J Thorac Cardiovasc Surg. 2006;132(4):769–75. CrossRefPubMed
12.
Zurück zum Zitat Le Pechoux CNP, Barlesi F, Faivre-Finn C, Lerouge D, Zalcman G, Antoni D, Lamezec B, Nestle U, Boisselier P, Thillays F, Paumier A, Dansin E, Peignaux K, Madelaine J, Pichon E, Larrouy A, Riesterer O, Lavole A, Bardet A. An international randomized trial, comparing post-operative conformal radiotherapy (port) to no port, in patients with completely resected non-small cell lung cancer (nsclc) and mediastinal n2 involvement: primary end-point analysis of lungart (ifct-0503, uk ncri, sakk). Ann Oncol. 2020;31(suppl_4):S1142–215. https://​doi.​org/​10.​1016/​annonc/​annonc325. CrossRef Le Pechoux CNP, Barlesi F, Faivre-Finn C, Lerouge D, Zalcman G, Antoni D, Lamezec B, Nestle U, Boisselier P, Thillays F, Paumier A, Dansin E, Peignaux K, Madelaine J, Pichon E, Larrouy A, Riesterer O, Lavole A, Bardet A. An international randomized trial, comparing post-operative conformal radiotherapy (port) to no port, in patients with completely resected non-small cell lung cancer (nsclc) and mediastinal n2 involvement: primary end-point analysis of lungart (ifct-0503, uk ncri, sakk). Ann Oncol. 2020;31(suppl_4):S1142–215. https://​doi.​org/​10.​1016/​annonc/​annonc325. CrossRef
13.
Zurück zum Zitat Saji H, Okada M, Tsuboi M, et al. Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial. Lancet. 2022;399(10335):1607–17. CrossRefPubMed Saji H, Okada M, Tsuboi M, et al. Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial. Lancet. 2022;399(10335):1607–17. CrossRefPubMed
14.
Zurück zum Zitat Nakamura K, Saji H, Nakajima R, et al. A phase iii randomized trial of lobectomy versus limited resection for small-sized peripheral non-small cell lung cancer (jcog0802/wjog4607l). Jpn J Clin Oncol. 2010;40(3):271–4. CrossRefPubMed Nakamura K, Saji H, Nakajima R, et al. A phase iii randomized trial of lobectomy versus limited resection for small-sized peripheral non-small cell lung cancer (jcog0802/wjog4607l). Jpn J Clin Oncol. 2010;40(3):271–4. CrossRefPubMed
15.
Zurück zum Zitat Yendamuri S, Dhillon SS, Groman A, et al. Effect of the number of lymph nodes examined on the survival of patients with stage i non-small cell lung cancer who undergo sublobar resection. J Thorac Cardiovasc Surg. 2018;156(1):394–402. CrossRefPubMed Yendamuri S, Dhillon SS, Groman A, et al. Effect of the number of lymph nodes examined on the survival of patients with stage i non-small cell lung cancer who undergo sublobar resection. J Thorac Cardiovasc Surg. 2018;156(1):394–402. CrossRefPubMed
16.
Zurück zum Zitat Osarogiagbon RU, Allen JW, Farooq A, Wu JT. Objective review of mediastinal lymph node examination in a lung cancer resection cohort. J Thorac Oncol. 2012;7(2):390–6. CrossRefPubMed Osarogiagbon RU, Allen JW, Farooq A, Wu JT. Objective review of mediastinal lymph node examination in a lung cancer resection cohort. J Thorac Oncol. 2012;7(2):390–6. CrossRefPubMed
17.
Zurück zum Zitat Osarogiagbon RU, Miller LE, Ramirez RA, et al. Use of a surgical specimen-collection kit to improve mediastinal lymph-node examination of resectable lung cancer. J Thorac Oncol. 2012;7(8):1276–82. CrossRefPubMed Osarogiagbon RU, Miller LE, Ramirez RA, et al. Use of a surgical specimen-collection kit to improve mediastinal lymph-node examination of resectable lung cancer. J Thorac Oncol. 2012;7(8):1276–82. CrossRefPubMed
18.
Zurück zum Zitat Osarogiagbon RU, Ramirez RA, Wang CG, et al. Dual intervention to improve pathologic staging of resectable lung cancer. Ann Thorac Surg. 2013;96(6):1975–81. CrossRefPubMed Osarogiagbon RU, Ramirez RA, Wang CG, et al. Dual intervention to improve pathologic staging of resectable lung cancer. Ann Thorac Surg. 2013;96(6):1975–81. CrossRefPubMed
19.
Zurück zum Zitat Osarogiagbon RU, Sareen S, Eke R, et al. Audit of lymphadenectomy in lung cancer resections using a specimen collection kit and checklist. Ann Thorac Surg. 2015;99(2):421–7. CrossRefPubMed Osarogiagbon RU, Sareen S, Eke R, et al. Audit of lymphadenectomy in lung cancer resections using a specimen collection kit and checklist. Ann Thorac Surg. 2015;99(2):421–7. CrossRefPubMed
20.
Zurück zum Zitat Lee JG, Lee CY, Park IK, et al. Number of metastatic lymph nodes in resected non-small cell lung cancer predicts patient survival. Ann Thorac Surg. 2008;85(1):211–5. CrossRefPubMed Lee JG, Lee CY, Park IK, et al. Number of metastatic lymph nodes in resected non-small cell lung cancer predicts patient survival. Ann Thorac Surg. 2008;85(1):211–5. CrossRefPubMed
21.
Zurück zum Zitat Nwogu CE, Groman A, Fahey D, et al. Number of lymph nodes and metastatic lymph node ratio are associated with survival in lung cancer. Ann Thorac Surg. 2012;93(5):1614–9. CrossRefPubMedPubMedCentral Nwogu CE, Groman A, Fahey D, et al. Number of lymph nodes and metastatic lymph node ratio are associated with survival in lung cancer. Ann Thorac Surg. 2012;93(5):1614–9. CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Whitson BA, Groth SS, Maddaus MA. Surgical assessment and intraoperative management of mediastinal lymph nodes in non-small cell lung cancer. Ann Thorac Surg. 2007;84(3):1059–65. CrossRefPubMed Whitson BA, Groth SS, Maddaus MA. Surgical assessment and intraoperative management of mediastinal lymph nodes in non-small cell lung cancer. Ann Thorac Surg. 2007;84(3):1059–65. CrossRefPubMed
Metadaten
Titel
Lymph node dissections and survival in sublobar resection of non-small cell lung cancer ≤ 20 mm
verfasst von
Shinkichi Takamori
Takefumi Komiya
Mototsugu Shimokawa
Emily Powell
Publikationsdatum
30.09.2022
Verlag
Springer Nature Singapore
Erschienen in
General Thoracic and Cardiovascular Surgery / Ausgabe 3/2023
Print ISSN: 1863-6705
Elektronische ISSN: 1863-6713
DOI
https://doi.org/10.1007/s11748-022-01876-6

Weitere Artikel der Ausgabe 3/2023

General Thoracic and Cardiovascular Surgery 3/2023 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.